

20 July 2016

News Release
For immediate release

**THOMSON MEDICAL AND UK-BASED CELL THERAPY LIMITED
COLLABORATE ON STEM CELL RESEARCH TO DEVELOP REGENERATIVE
MEDICINES**


London, 20 July 2016 – Thomson Medical Pte Ltd (Thomson) and its associated company in Malaysia, TMC Life Sciences Bhd (TMCLS) inked Memoranda of Understanding (MOU) with UK-based Cell Therapy Limited (CTL) to collaborate on research and development in the biomedical and health sciences space.

2. Under the terms of the MOU, CTL will develop programmes to train medical professionals in the partner hospitals (Thomson and TMCLS) in regenerative medicine and stem cell technology. Thomson and TMCLS will in turn provide CTL with the relevant platform to facilitate stem cell research and development in Singapore and Malaysia.

3. CTL's research will focus on cardiovascular and orthopaedic conditions and seek to reduce the rate of morbidity and mortality in patients through appropriate regenerative interventions. In May 2016, Cell Therapy signed a licensing deal with major Japanese pharmaceutical company Daiichi Sankyo for the Japanese rights to its stem cell therapy for heart failure.

4. Mr Roy Quek, Chairman of Thomson Medical Pte Ltd, said: "Our stem cell research and development partnership with Cell Therapy is part of Thomson's larger strategic vision to develop new and stronger capabilities to deliver higher quality medical care and outcomes. Cell Therapy counts prominent biomedical pioneers in its ranks, including Nobel Laureate Sir Martin Evans, and shares our vision of building a better and healthier tomorrow for patients. This is an exciting partnership and I look forward to working closely with the team from Cell Therapy."

5. Mr Ajan Reginald, Chief Executive Officer, Cell Therapy Ltd, said: "Asia is a critical region for Cell Therapy. This is a strategic partnership with Thomson and TMCLS, which are among the fastest growing private medical groups in Southeast Asia. The partnership will accelerate access to Heartcel for more than 10 million patients in Southeast Asia with heart disease through clinical trials, physician education and innovation collaborations. It underlines CTL's commitment to bring lifesaving medicines to patients world-wide."



From left to right: Mr Mark Beards, Corporate Development Director, Cell Therapy Ltd, Mr Roy Quek, Chairman of Thomson and Executive Director/Group Chief Executive Officer of TMCLS, Mr Ajan Reginald, Chief Executive Officer, Cell Therapy Ltd, Dr Chan Boon Kheng, Group President, Thomson at the signing of the MOU

Media contact:

Warren Wu, Corporate Marketing and Communications, Thomson Medical Pte Ltd

- Phone: +65 6511 3147 or +65 9170 0175
- Email: warrenwu@thomsonmedical.com

About Thomson Medical Pte Ltd

Incorporated in 1977, Thomson Medical is one of Singapore's leading providers of healthcare services for women and children. It owns and operates Thomson Medical Centre, a fully integrated hospital that provides a comprehensive range of facilities and services with a focus on obstetrics and gynaecology (O&G) and paediatric services.

Over the years, Thomson Medical has expanded its operations to include new areas of specialties and services to care for women beyond maternity and their families across generations. These include an island-wide network of Thomson Women's Clinics and related specialty centres: Thomson Chinese Medicine, Thomson Dental Centre, Thomson Diagnostic Imaging Centre, Thomson Diagnostic Ultrasound Centre, Thomson Fertility Centre, Thomson Lifestyle Centre, Thomson Paediatric Centre, Thomson ParentCraft Centre, Thomson Pre-Natal Diagnostic Laboratory, Thomson Specialist Dentistry, Thomson Specialist Skin Centre, Thomson Well Women Clinic and Thomson Women Cancer Centre.

For more information, please visit: <http://www.thomsonmedical.com/>

About Cell Therapy Ltd

Cell Therapy Limited (CTL) is a private British regenerative medicine company that has discovered and developed a pipeline of novel cellular medicines in areas of high unmet clinical need. CTL was founded in 2009 by Nobel Laureate Professor Sir Martin Evans and former Roche Global Head of Emerging Technologies Ajan Reginald. CTL is governed by a six-member Board of Directors comprised of top corporate talent and is chaired by former United Kingdom Minister of State for Trade & Investment, Lord Digby Jones of Birmingham. CTL's disruptive technology platform drives in-house discovery and manufacture of a pipeline of novel tissue-specific regenerative medicines. CTL is currently in the process of re-branding under the name Celixir.

– end –